Lloyd Sanders Named New CEO of Epic Sciences

Sanders comes to Epic from Myriad Genetics where he served as president of the company’s oncology segment.

ArcherDx, UCL Collaborate on ctDNA Lung Cancer Study

The collaboration with the University College London (UCL) and the Francis Crick Institute will use ArcherDX's proprietary Anchored Multiplex PCR (AMP) technology to detect evidence of disease recurrence in lung cancer patients using cell-free circulating tumor DNA (ctDNA) as part of the UCL-sponsored TRACERx clinical study.


Magazine Post 8

Magazine Post 6

Magazine Post 5